Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | GBA1 | P04062 | 14/20 | 0.38 |
| ▸ | GBA2 | Q9HCG7 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30064858 | 1.00 | GAA (0.41) | GAATHRBGBA1GBA2POLB | |
| SCHEMBL3317512 | 1.00 | GAA (0.41) | GAATHRBGBA1GBA2POLB | |
| SCHEMBL16279687 | 1.00 | GAA (0.41) | GAATHRBGBA1GBA2POLB | |
| SCHEMBL25237187 | 0.88 | POLB (0.46) | GAATHRBGBA1GBA2POLB | |
| SCHEMBL3360203 | 0.82 | GBA1 (0.42) | GAATHRBGBA1GBA2 | |
| SCHEMBL16277708 | 0.82 | PLG (0.32) | — | |
| SCHEMBL13942058 | 0.82 | GBA1 (0.42) | GAATHRBGBA1GBA2 | |
| SCHEMBL15186923 | 0.82 | GBA1 (0.42) | GAATHRBGBA1GBA2 | |
| SCHEMBL3360199 | 0.82 | GBA1 (0.42) | GAATHRBGBA1GBA2 | |
| SCHEMBL13032050 | 0.79 | GBA1 (0.42) | GAATHRBGBA1GBA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3559007-B1 | SULFONAMIDE COMPOUNDS HAVING TNAP INHIBITORY ACTIVITY | DAIICHI SANKYO CO LTD (JP) | 2023-08-16 | — | — | EP | disclosed |
| US-11046710-B2 | Sulfonamide compounds | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2021-06-29 | — | — | US | disclosed |
| US-11014939-B2 | — | — | 2021-05-25 | — | — | US | disclosed |
| US-10927109-B2 | 7-substituted 1-aryl-naphthyridine-3-carboxylic acid amides and use thereof | BAYER AKTIENGESELLSCHAFT (DE) | 2021-02-23 | — | — | US | disclosed |
| US-20200087321-A1 | SULFONAMIDE COMPOUNDS | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2020-03-19 | — | — | US | disclosed |
| US-20190263805-A1 | 7-SUBSTITUTED 1-ARYL-NAPHTHYRIDINE-3-CARBOXYLIC ACID AMIDES AND USE THEREOF | BAYER AKTIENGESELLSCHAFT (DE) | 2019-08-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190263805-A1 | 7-SUBSTITUTED 1-ARYL-NAPHTHYRIDINE-3-CARBOXYLIC ACID AMIDES AND USE THEREOF | AADAC, GLS, NAT1 | GAA 136/4885THRB 2293/4885GBA1 691/4885 |
| US-20200087321-A1 | SULFONAMIDE COMPOUNDS | ALPI, ASAH2, STS | GAA 82/4885THRB 3795/4885GBA1 142/4885 |
| US-11014939-B2 | — | ALPI, ALPP, ACER2 | GAA 84/4885THRB 3189/4885GBA1 505/4885 |
| US-11046710-B2 | Sulfonamide compounds | ALPI, ASAH2, STS | GAA 82/4885THRB 3795/4885GBA1 142/4885 |
| US-10927109-B2 | 7-substituted 1-aryl-naphthyridine-3-carboxylic acid amides and use thereof | AADAC, GLS, NAT1 | GAA 136/4885THRB 2293/4885GBA1 691/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.